The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure
Open accessAbstract
Background: Depression is a prevalent neuropsychiatric disorder that affects an estimated 350 million people worldwide. Currently available treatments for depression are lacking in both speed of onset and efficacy. Recent pharmacological efforts have targeted the glutamatergic neurotransmitter system using the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine to produce rapid and robust antidepressant effects, however the widespread clinical use of ketamine is limited due to side effects and abuse liability. More recently, work evaluating metabotropic mGluR2/3 receptor antagonists has demonstrated many similarities with ketamine. Methods: Male, Sprague–Dawley rats were exposed to a chronic unpredictable stress paradigm, which produces decreased sucrose preference, a measure of anhedonia. Rats were then treated with vehicle or a single injection of the mGluR2/3 antagonist LY341495 (3 mg/kg, i.p.) and tested at 24 hrs, 48 hrs or 10 days after a single treatment. Results: We demonstrate that a single treatment with LY341495 produces a rapid (within 1–2 days) and long-lasting (10 days) reversal of anhedonia caused by chronic unpredictable stress in rats. This model provides a rigorous test of rapid-acting agents as typical antidepressants require several weeks of treatment to produce a response. Conclusions: These data suggest that LY341495 has the ability to produce rapid and robust antidepressant effects similar to ketamine. Together, the results highlight the potential for similar compounds to produce rapid and lasting efficacy for the treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LY341495 (3 mg/kg i.p.) in rats was sufficient to reverse anhedonia produced by a chronic unpredictable stress model of depression and measured using the sucrose preference test at 48 hours post-treatment (Dwyer et al., 2013).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Dwyer et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“Major Depressive Disorder (MDD) is a debilitating neuropsychiatric disorder that affects nearly one fifth of the US population [1], and according to the World Health Organization (WHO), affects an estimated 350 million people worldwide, making it the leading cause of disability.”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 6×
“The discovery that the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine produces rapid antidepressant effects in humans (within 2 hours) that last roughly one week after a single intravenous administration has generated interest in targeting the glutamatergic system for the treatment of MDD [2,…”
BackgroundInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 6×
“The discovery that the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine produces rapid antidepressant effects in humans (within 2 hours) that last roughly one week after a single intravenous administration has generated interest in targeting the glutamatergic system for the treatment of MDD [2,…”
BackgroundInfluentialmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“through the mechanistic target of rapamycin complex 1 (mTORC1) pathway [4,5], which is a ubiquitously expressed serine/threonine kinase pathway involved in regulation of cell growth and protein translation.”
BackgroundSelf-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Much like ketamine, mGluR2/3 antagonists produce rapid and transient increases in glutamate release in the mPFC [13,14].”
BackgroundShigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P. J., Neki, A., Abe, T., Nakanishi, S., et al. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07503.1997 · Cited by 1,116 · cited 1×
“The mGluR2 receptor is located pre- and post-synaptically [6] but is thought to be predominantly located at the pre-terminal portion of axons [7] where it functions as an autoreceptor.”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“Blockade of post-synaptic AMPA receptors blocks the antidepressant effects of both ketamine and mGluR2/3 antagonists in rodent models [15,16].”
BackgroundLi, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082 · cited 4×
“This rapid effect of LY341495 is similar to that observed following ketamine treatment as previous studies have shown a reversal of the deficit in sucrose preference within 24 hrs of ketamine treatment [4].”
BackgroundResultInfluentialSelf-citationOhishi, H., Shigemoto, R., Nakanishi, S., & Mizuno, N. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90485-x · Cited by 560 · cited 1×
“While mGluR2 expression seems to be confined to neurons [8], mGluR3 receptors, which are also pre- and post-synaptic, are located on neurons as well as glia [9].”
Background
Cited by
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity
Gerhard, D. M., Wohleb, E. S., & Duman, R. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.016 · Cited by 261
“LY341495 also rapidly reverses the anhedonia caused by chronic stress exposure, a rigorous rodent test of rapid antidepressant actions [84].”
BackgroundSelf-citationDuman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
Self-citationKetamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
“Preclinical studies have reported that mGluR2/3 antagonists, notably LY341,495 and MGS0039, produce antidepressant effects in a number of rodent models, including the FST, NSFT, and a chronic unpredictable stress-anhedonia model, and also require mTORC1 signaling 29,63,64 .”
BackgroundSelf-citationLindsley, C. W., Emmitte, K. A., Hopkins, C. R., Bridges, T. M., Gregory, K. J., Niswender, C. M., & Conn, P. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00656 · Cited by 181
Metadata
- Authors
- Dwyer, J. M., Lepack, A. E., & Duman, R. S.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S
- Venue
- Journal of Molecular Psychiatry
- Published
- 2013-09-17
- Volume
- 1
- Issue
- 1
- Pages
- 15-15
- ISSN
- 2049-9256 (ISSN-L)
- PMC
- PMC4224009
- OpenAlex
- W2120091916
- Cited by
- 81
- References
- 21
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 11 · 2021: 9 · 2020: 8 · 2019: 11 · 2018: 5 · 2017: 9 · 2016: 7 · 2015: 9 · 2014: 2
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Journal of Molecular Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- National Institute of Mental Health (R01MH093897, R01MH105910)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- LY341495, anhedonia, chronic unpredictable mild stress, depression, rapid-acting antidepressants, ketamine, metabotropic glutamate receptors, sucrose preference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. https://app.cochat.ai/papers/10.1186/2049-9256-1-15
- The paper
- Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2013). mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. Journal of Molecular Psychiatry. https://doi.org/10.1186/2049-9256-1-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.